Clinical Trial Update: Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update concerns autologous CD19 CAR-T cell therapy with an inducible safety switch for relapsed/refractory acute lymphoblastic leukemia. The…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Autologous CD19 CAR-T cell therapy with inducible safety switch (CD19-targeted autologous CAR-T cell therapy with inducible safety switch)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Acute Lymphoblastic Leukemia, Immune System Diseases | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING